Guo Tao, Dong Xue, Shi Gang
Department of Gynecology, West China Second University Hosipital, Sichuan University, Chengdu 610041, China.
Key Laboratory of Birth Defects and Related Diseases of Woman and Children (Sichuan University), Ministry of Education, Chengdu 610041, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jul;49(4):551-555.
To explore the effects of fisetin and fisetin nanopartical on anti-proliferation and apoptosis induction of human ovarian cancer cell line SKOV3.
The MTT assay was used to determine the survival rate of SKOV3 cell through apoptosis induction after fisetin and fisetin nanopartical treatment, and the drug concentration of the next experiment was selected. 15 nude mice vaccinated SKOV3 cells mixture mode randomly into three groups, treatment began on the fifth day, every 3 d injection times, each time 0.2 mL, a total of 12 times. Group A for the control (50 mL/L glucose solution), group B for fisetin (1.25 mg/kg), group C for fisetin nanopartical (1.25 mg/kg). After the treatment, tumor quality was recorded, and histopathological lesions were observed by HE staining on heart, liver, spleen, lung and kidney sections. The proliferation of SKOV3 cells was detected by Ki67 immunohistochemical staining in tumor tissue sections, and apoptosis of SKOV3 cells was detected by TUNEL assay.
MTT test indicated that fisetin and fisetin nanopartical had inhibition effect on ovarian cancer cell in a dose-dependent manner. The half-maximal inhibitory concentration (IC) value for fisetin and fisetin nanopartical were 125-250 μg/mL and 62.5-125 μg/mL. Therefore, the working concentration was selected as 125 μg/mL. 11 mice were completed and survived until the end of the experiment (3 in group A, 4 in group B, 4 in group C). Group A nude mice abdominal cavity in cauliflower shape tumor nodules, B and C group only tiny granule tumor nodules, B and C group of intraperitoneal tumor mass is quite (>0.05), but were lower than group A (<0.05). No obvious damage was found in the hepatocytes, liver, spleen, lung, and kidney slices. Compared with group A, Ki67 index in group B and group C decreased, and cell apoptosis rate increased (<0.05), but there was no significant difference between group B and group C (>0.05).After treatment of fisetin and fisetin nanopartical, heart, liver, spleen, lung and kidney are safe without damage.
Fisetin and fisetin nanopartical have the effect of anti-ovarian cancer cells, and no organ damage has been found in both.
探讨非瑟酮及其纳米颗粒对人卵巢癌细胞系SKOV3增殖及凋亡的影响。
采用MTT法检测非瑟酮及其纳米颗粒作用于SKOV3细胞诱导凋亡后的生存率，并据此选择下一实验的药物浓度。将15只接种SKOV3细胞混合物的裸鼠随机分为3组，于第5天开始治疗，每3天注射1次，每次0.2 mL，共注射12次。A组为对照组（50 mL/L葡萄糖溶液），B组为非瑟酮组（1.25 mg/kg），C组为非瑟酮纳米颗粒组（1.25 mg/kg）。治疗后记录肿瘤质量，并对心、肝、脾、肺、肾切片进行HE染色观察组织病理学损伤。通过肿瘤组织切片的Ki67免疫组化染色检测SKOV3细胞的增殖情况，采用TUNEL法检测SKOV3细胞的凋亡情况。
MTT试验表明，非瑟酮及其纳米颗粒对卵巢癌细胞具有剂量依赖性抑制作用。非瑟酮及其纳米颗粒的半数抑制浓度（IC）值分别为125 - 250 μg/mL和62.5 - 125 μg/mL。因此，选择125 μg/mL作为工作浓度。11只小鼠完成实验并存活至实验结束（A组3只，B组4只，C组4只）。A组裸鼠腹腔内有菜花状肿瘤结节，B组和C组仅有微小颗粒状肿瘤结节，B组和C组腹腔内肿瘤质量相当（>0.05），但均低于A组（<0.05）。心、肝、脾、肺、肾切片未见明显损伤。与A组相比，B组和C组的Ki67指数降低，细胞凋亡率升高（<0.05），但B组和C组之间差异无统计学意义（>0.05）。非瑟酮及其纳米颗粒治疗后，心、肝、脾、肺、肾均安全无损伤。
非瑟酮及其纳米颗粒具有抗卵巢癌细胞的作用，且两者均未发现器官损伤。
